Circulating hepcidin-25 is reduced by endogenous estrogen in humans

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Lehtihet, Mikael ^a   Bonde, Ylva ^a   Beckman, Lena ^a   Berinder, Katarina ^a   Hoybye, Charlotte ^a   Rudling, Mats ^a   Sloan, John H ^b   Konrad, Robert J ^b   Angelin, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FERRITIN; HEPCIDIN; HEPCIDIN 25; IRON; PROLACTIN; THYROXINE; TRANSFERRIN; UNCLASSIFIED DRUG; HEPCIDIN 25, HUMAN; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; FERRITIN BLOOD LEVEL; FERTILIZATION IN VITRO; FREE THYROXINE INDEX; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPERTHYROIDISM; IMMUNOASSAY; IRON BLOOD LEVEL; MALE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; SANDWICH IMMUNOASSAY; TRANSFERRIN BLOOD LEVEL; ADOLESCENT; AGED; ANEMIA; BIOSYNTHESIS; BLOOD; CHEMISTRY; COMPLICATION; DEFICIENCY; IN VITRO FERTILIZATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; C-REACTIVE PROTEIN; DOPAMINE AGONISTS; ESTROGENS; FEMALE; FERRITINS; FERTILIZATION IN VITRO; HEPCIDINS; HUMAN GROWTH HORMONE; HUMANS; HYPERPROLACTINEMIA; HYPERTHYROIDISM; IMMUNOASSAY; IRON; MALE; MIDDLE AGED; PROLACTINOMA; TRANSFERRIN; YOUNG ADULT;

EID: 84959422962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148802     Document Type: Article

References (39)

1. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008; 93(1):90-7. doi: 10.3324/haematol.11705 PMID: 18166790.
2. Qiao B, Sugianto P, Fung E, Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell metabolism. 2012; 15(6):918-24. doi: 10.1016/j.cmet.2012.03.018 PMID: 22682227; PubMed Central PMCID: PMC3372862.
3. Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell metabolism. 2012; 15(6):905-17. doi: 10.1016/j.cmet.2012.03.017 PMID: 22682226.
4. Goyal J, McCleskey B, Adamski J. Peering into the future: hepcidin testing. American journal of hematology. 2013; 88(11):976-8. doi: 10.1002/ajh.23519 PMID: 23798368.
5. Kasvosve I. Effect of ferroportin polymorphism on iron homeostasis and infection. Clinica chimica acta; international journal of clinical chemistry. 2013; 416:20-5. doi: 10.1016/j.cca.2012.11.013 PMID: 23178444.
6. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS letters. 2000; 480(2-3):147-50. PMID: 11034317.
7. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. The Journal of biological chemistry. 2001; 276(11):7806-10. doi: 10.1074/jbc.M008922200 PMID: 11113131.
8. Atanasiu V, Manolescu B, Stoian I. Hepcidin-central regulator of iron metabolism. European journal of haematology. 2007; 78(1):1-10. doi: 10.1111/j.1600-0609.2006.00772.x PMID: 17042775.
9. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. The Journal of clinical endocrinology and metabolism. 2010; 95(10):4743-7. doi: 10.1210/jc.2010-0864 PMID: 20660052; PubMed Central PMCID: PMC3050108.
10. Troutt JS, Rudling M, Persson L, Stahle L, Angelin B, Butterfield AM, et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clinical chemistry. 2012; 58(8):1225-32. doi: 10.1373/clinchem.2012.186866 PMID: 22679180.
11. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging cell. 2013; 12(2):280-91. doi: 10.1111/acel.12052 PMID: 23399021; PubMed Central PMCID: PMC3602280.
12. Beggs LA, Yarrow JF, Conover CF, Meuleman JR, Beck DT, Morrow M, et al. Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone. American journal of physiology Endocrinology and metabolism. 2014; 307(5):E456-61. doi: 10.1152/ajpendo. 00184.2014 PMID: 25074984; PubMed Central PMCID: PMC4154071.
13. Nishioka H, Haraoka J. Hypopituitarism and anemia: effect of replacement therapy with hydrocortisone and/or levothyroxine. Journal of endocrinological investigation. 2005; 28(6):528-33. PMID: 16117194.
14. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws ER Jr. Anemia, testosterone, and pituitary adenoma in men. Journal of neurosurgery. 2003; 98(5):974-7. doi: 10.3171/jns.2003.98.5. 0974 PMID: 12744356.
15. Ten Have SM, van der Lely AJ, Lamberts SW. Increase in haemoglobin concentrations in growth hormone deficient adults during human recombinant growth hormone replacement therapy. Clinical endocrinology. 1997; 47(5):565-70. PMID: 9425396.
16. Gianoukakis AG, Leigh MJ, Richards P, Christenson PD, Hakimian A, Fu P, et al. Characterization of the anaemia associated with Graves' disease. Clinical endocrinology. 2009; 70(5):781-7. doi: 10.1111/j.1365-2265.2008.03382.x PMID: 18710465; PubMed Central PMCID: PMC3712752.
17. Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Archives of internal medicine. 1999; 159(15):1726-30. PMID: 10448775.
18. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology. 2012; 153(7):3170-8. doi: 10.1210/en.2011-2045 PMID: 22535765; PubMed Central PMCID: PMC3380311.
19. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. The Journal of biological chemistry. 2001; 276(11):7811-9. doi: 10.1074/jbc.M008923200 PMID: 11113132.
20. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature genetics. 2003; 34(1):97-101. doi: 10.1038/ng1150 PMID: 12704388.
21. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007; 46(4):1291-301. doi: 10.1002/hep.21886 PMID: 17886335.
22. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, et al. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clinical chemistry. 2010; 56(11):1725-32. doi: 10.1373/clinchem.2010.151522 PMID: 20847326.
23. Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011; 14 (3):199-207. doi: 10.1007/s11102-010-0277-9 PMID: 21128120.
24. Bonde Y, Breuer O, Lutjohann D, Sjoberg S, Angelin B, Rudling M. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. Journal of lipid research. 2014; 55(11):2408-15. doi: 10.1194/jlr.M051664 PMID: 25172631.
25. Lundberg J, Hoybye C, Krusenstjerna-Hafstrom T, Bina HA, Kharitonenkov A, Angelin B, et al. Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. Journal of internal medicine. 2013; 274(3):227-32. doi: 10.1111/joim.12112 PMID: 23844970.
26. Persson L, Henriksson P, Westerlund E, Hovatta O, Angelin B, Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32(3):810-4. doi: 10.1161/ATVBAHA.111.242461 PMID: 22207727.
27. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta endocrinologica. 1991; 124(6):620-9. PMID: 2068892.
28. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011; 117(25): e218-25. doi: 10.1182/blood-2011-02-337907 PMID: 21527524.
29. Rigas AS, Sorensen CJ, Pedersen OB, Petersen MS, Thorner LW, Kotze S, et al. Predictors of iron levels in 14,737 Danish blood donors: results from the Danish Blood Donor Study. Transfusion. 2014; 54 (3 Pt 2):789-96. doi: 10.1111/trf.12518 PMID: 24372094.
30. Schumann K, Ettle T, Szegner B, Elsenhans B, Solomons NW. On risks and benefits of iron supplementation recommendations for iron intake revisited. Journal of trace elements in medicine and biology: organ of the Society for Minerals and Trace Elements. 2007; 21(3):147-68. doi: 10.1016/j.jtemb.2007. 06.002 PMID: 17697954.
31. Milman N, Kirchhoff M, Jorgensen T. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Annals of hematology. 1992; 65(2):96-102. PMID: 1511065.
32. Qian Y, Yin C, Chen Y, Zhang S, Jiang L, Wang F, et al. Estrogen contributes to regulating iron metabolism through governing ferroportin signaling via an estrogen response element. Cellular signalling. 2015; 27(5):934-42. doi: 10.1016/j.cellsig.2015.01.017 PMID: 25660146.
33. Latour C, Kautz L, Besson-Fournier C, Island ML, Canonne-Hergaux F, Loreal O, et al. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology. 2014; 59(2):683-94. doi: 10.1002/hep.26648 PMID: 23907767.
34. Smitz J, Andersen AN, Devroey P, Arce JC, Group M. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Human reproduction. 2007; 22(3):676-87. doi: 10.1093/humrep/del445 PMID: 17110397.
35. Mattace Raso G, Irace C, Esposito E, Maffettone C, Iacono A, Di Pascale A, et al. Ovariectomy and estrogen treatment modulate iron metabolism in rat adipose tissue. Biochemical pharmacology. 2009; 78(8):1001-7. doi: 10.1016/j.bcp.2009.05.034 PMID: 19501056.
36. Hou Y, Zhang S, Wang L, Li J, Qu G, He J, et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene. 2012; 511(2):398-403. doi: 10.1016/j.gene.2012.09.060 PMID: 23041085.
37. Ricoux R, Pontet M, Tresca JP, Engler R. [Plasma concentration of C-reactive protein in patients with high estrogen levels]. Annales de biologie clinique. 1994; 52(2):125-8. PMID: 7802339.
38. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. The Journal of clinical endocrinology and metabolism. 2008; 93(5):1702-10. doi: 10.1210/jc.2007-2193 PMID: 18303079.
39. Golde DW, Bersch N, Li CH. Growth hormone: species-specific stimulation of erythropoiesis in vitro. Science. 1977; 196(4294):1112-3. PMID: 870971.